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Objectives Acute pain management in opioid users can be challenging in the periop-
erative period. This study focuses on whether use of opioids increases sedation medi-
cation requirements in patients undergoing port placement under moderate sedation.
Materials and Methods A retrospective review was performed on all patients under-
going port placement between June 1, 2017, and June 30, 2019. Exclusion criteria 
included receiving general anesthesia, no sedation, and errors in data entry. Data 
collection included demographics, use of opioids, benzodiazepines, antidepressants, 
tobacco, alcohol, and sedation data.
Results Opioid, benzodiazepine, and selective serotonin reuptake inhibitors 
(SSRIs)/serotonin-norepinephrine reuptake inhibitors (SNRIs) use was significantly 
associated with higher sedation drug dose requirements. Patients using opioids 
required 10.5% higher doses of midazolam compared with nonusers. Benzodiazepine 
users required 16.3% additional dosage of midazolam than nonusers. Finally, patients 
on SSRIs/SNRIs medications required 11.8% higher midazolam dosing when compared 
with nonusers.
Conclusion Anticipating higher needs of sedation medications during procedures in 
patients with history of psychotropic agents use can allow for more effective sedation 
and patient satisfaction. More patient and provider awareness is needed on this topic, 
as health care policy is moving toward value-based healthcare, with patient satisfac-
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Introduction
Opioids are often used perioperatively–short term in acute 
postprocedure period or long term in patients with cancer 
related pain or palliative care.1 In the past several decades, 
there has been an increase in opioid use for chronic non-
cancer-related pain; this trend has only recently started to 
decrease with improved utilization of nonopioid, nonphar-
macologic interventions, and implementation of clinical 
guidelines in using opioids.1-4 Overall opioid prescriptions 
have increased from 2006 and peaked in 2012 at more than 
255 million dispensed prescriptions. It downtrended from 
2012 with 168 million prescriptions dispensed in 2018.5 
With use of opioids, there is concern for tachyphylaxis, depen-
dence, opioid-induced hyperalgesia, and even opioid-related 
respiratory depression and death.6,7 Opioid tolerance, as 
defined by FDA, occurs when an individual takes ≥1 week of 
the following agents and doses: 30 mg oral oxycodone/day, 
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25 mcg transdermal fentanyl/hour, 60 mg oral morphine/day, 
or an equivalent dose of a different opioid.8 Therefore, even 
short courses of opioids can result in tolerance with patients 
requiring higher doses to achieve similar analgesic effect.7 
This pattern has been seen in patients taking opioids for both 
cancer and noncancer-related pain.9
Pain management during perioperative period can 
be challenging in patients who have history of prescrip-
tion opioid use, opioid misuse, or even those on opioid 
agonist/antagonist regimens for withdrawal and cessation.6  
Different levels of sedation ranging from minimal sedation 
to general anesthesia need to be performed, based on proce-
dure type to provide adequate sedation and analgesia during 
procedures.6,10 Moderate sedation is used frequently for 
minimally invasive procedures including endoscopies, bron-
choscopies, port placements, central line placements, percuta-
neous biopsies (i.e., liver, kidney, lung), and drain placements, 
etc.10-12 Benzodiazepines and opioids are used during moder-
ate sedation, wherein patients are easily arousable to verbal 
and tactile stimuli and are able to protect their airway and 
maintain spontaneous ventilation.10 Benzodiazepines and 
opioids have several therapeutic effects, and the anxiolytic 
effects of benzodiazepines allows for decreased perception 
of pain by working synergistically with opioid and nonopi-
oid analgesic medications.10,13,14 Adequate sedation allows for 
timely and ease in procedure completion while minimizing 
patient discomfort.10
Higher sedation requirements in patients with history 
of opioid and alcohol use disorders has been documented 
during colonoscopies and mechanical ventilation.11,15 Other 
factors contributing to higher sedation requirements include 
anxiety, agitation, and pre-existing high pain sensitivity; 
some of these patients even have a history of concomitant 
use of benzodiazepines and antidepressants.11,16
The purpose of this study is to evaluate whether use of 
opioids would increase sedation medication requirements 
in patients undergoing minimally invasive procedures under 
moderate sedation at a single tertiary care center. We elected 
central venous port placement as an index minimally inva-
sive procedure to decrease procedural heterogeneity.
Materials and Methods
Patient Selection and Data Collection
Following approval from local Institutional Review Board, a 
retrospective study was performed on all the patients who 
had port placement between June 1, 2017, and June 30, 
2019 at a single tertiary care center. Informed consent was 
obtained from all patients included in the study prior to per-
forming procedure and data collection. A total of 430 different 
instances of port placement occurred during this time 
period. Patients with known history of illicit opioid use and 
patients who had no sedation or required general anesthesia 
were excluded from the current study. In addition, cases with 
errors in data entry at time of procedure were also excluded. 
Based on these criteria, a total of 27 cases were excluded.
For the remaining 403 patients, electronic medi-
cal records were reviewed for following data collection: 
patient demographics, use of tobacco, alcohol use, and seda-
tion data (amounts of midazolam, fentanyl, and diphenhydr-
amine). A procedural nurse administered moderate sedation 
medications during port placement and a pain scale (1–10) 
goal of < 4 was used as the target for adequate sedation. 
All the providers had at least 3 years of postinterventional 
radiology fellowship experience. The following definitions 
were used for opioids and other psychotropic substances. 
Use of opioids was defined as prescribed opioids for ≥ 1 week 
within the last 3 years prior to port placement. Additional 
data collected included use of benzodiazepines (defined as 
current or history of use of benzodiazepine products for at 
least 7 days within 5 years prior to date of port placement), 
use of typical antidepressants (defined as current or history 
of use of selective serotonin reuptake inhibitors [SSRIs] and 
serotonin-norepinephrine reuptake inhibitors [SNRIs] for at 
least 7 days within 5 years prior to date of port placement), 
and any documented history of use of pregabalin/gabapentin.
Statistical Analysis
Statistical analysis was performed using SAS software 
version 9.4 (SAS Institute Inc., Cary, NC, USA). t-tests were 
used to identify average doses of midazolam and fentanyl 
used in patients with use of opioids and other psychotropic 
substances including benzodiazepines, gabapentin/pregaba-
lin, and antidepressants. Overall mean, standard deviations, 
and p values were calculated using SAS software. Significance 
was indicated by a p value of ≤ 0.05.
Results
Of the 403 remaining port placements, the following were 
the patient demographics: 44% were male, 92% Caucasian, 7% 
African-American and 1% Asian; 18% had history of alcohol 
abuse and 53% had history of tobacco use. Of the 403 cases, 
185/403 (46%) had used opioids for at least 1 week in the 
3 years prior to port placement, 81/403 (20%) had used ben-
zodiazepines for at least 1 week in the 5 years prior to port 
placement, 81/403 (20%) of the patients had used antidepres-
sants for at least 7 days in the 5 years prior to port placement, 
and 44/403 (11%) had used gabapentin/pregabalin.
Statistical analysis was performed using SAS soft-
ware. Patients who were opioid users needed 10.5% sig-
nificantly higher doses of midazolam when compared 
with nonusers (p value = 0.04), and these patients also 
required 7.9% higher doses of fentanyl compared with nonus-
ers; however, the latter results were not statistically significant 
(p value = 0.09). Patients who had history of use of benzo-
diazepines required 11.3% significantly higher doses of fen-
tanyl and 16.3% significantly higher doses of midazolam 
when compared with nonusers (p value = 0.05 and 0.01, 
respectively). Finally, patients with history of antidepressant 
use required 11.9% significantly higher doses of midazolam 
and 7.8% higher doses of fentanyl when compared with non-
users, however, the latter was not statistically significant 
(p values 0.05 and 0.17, respectively). Patients who were 
users of pregabalin/gabapentin required higher doses of 
fentanyl and midazolam when compared with nonusers; 
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however, these results were not statistically significant. 
►Table 1 demonstrates average dose of midazolam and fen-
tanyl with associated standard deviations and p values in 
patients with use of opioids and other psychotropic agents.
Discussion
After heart disease, cancer is the most common cause of 
death with an estimated approximately 600,000 deaths 
expected in 2020.17 However, given advances in treatment, 
earlier detection of disease, improvement in screening 
modalities, and decrease in risk factors such as smoking, 
cancer death continues to decrease. This has resulted in 
greater number of cancer survivors, thus resulting in a 
greater number of patients managing cancer-related pain on 
a day-to-day basis.9,17 Opioids continue to be one of the pri-
mary mainstays in treatment of severe cancer-related pain 
when nonopioid interventions have failed or to augment 
these interventions for breakthrough pain. In addition, there 
has been an overall increase in prescription of benzodiaz-
epines over the past several decades. One study reported 
a 67% increase in number of individuals filling benzodiaz-
epine prescriptions from 1996 to 2013.18 During the same 
time period, the study noted three times increase in the 
quantity of benzodiazepines filled due to increase in dosage, 
number of prescriptions, duration of prescriptions, or a com-
bination of these factors.18
Tachyphylaxis, physical dependence, opioid-induced 
hyperalgesia, addiction, and overdose continue to be concern-
ing factors with use of opioids. A single dose may be sufficient 
to develop tolerance for some opioid effects; however, in most 
cases, development of tolerance depends on duration, dose, 
and type of opioid utilized.3 Tolerance to effects of analgesia and 
euphoria occur earlier than effects of respiratory depression; 
thus, the increasing concern for overdose when dose escala-
tion occurs.3 It is believed that dose escalation up to 10 times 
initial dose may be required for similar analgesic effects.3 
However, following cessation of opioid use, effects of toler-
ance and dependence resolve within days to weeks, depend-
ing on strength, duration and type of opioid used.3
Various studies have looked at sedation in patients 
with history of substance use disorders in various settings 
including endoscopies, mechanically ventilated patients, 
and dental procedures.11,15,19 Patel et al demonstrated that 
during sedation for colonoscopies, opioid users require sig-
nificantly higher doses of fentanyl (by 23%) and midazolam 
(by 24%) compared with patients with alcohol use and 
control groups.11 This is consistent with findings from this 
current study, and it demonstrates significantly increased 
requirement of midazolam by 10.5% in patients who are 
opioid users in comparison to nonusers during port place-
ment. These patients also had required 7.9% increase in fen-
tanyl dosing; however, these results were not significant at 
the 95% confidence interval. Another study demonstrated 
that during mechanical ventilation in intensive care unit, 
patients with alcohol use disorder needed greater amounts 
of sedatives and opioids to achieve similar degree of seda-
tion than their nonalcoholic counterparts.15 Cook et al also 
demonstrated that greater amounts of diazepam are required 
to achieve similar levels of sedation in patients using alcohol 
and benzodiazepines even at low doses when these patients 
are undergoing elective dental and endoscopic procedures.19  
These results are similar to the current study. Patients who 
had history of benzodiazepine use required 11.3% signifi-
cantly higher doses of fentanyl and 16.3% significantly 
higher doses of midazolam when compared with nonusers. 
Tolerance has been attributed to increased requirements 
of sedatives in patients with history of benzodiazepine 
use.19,20 Sedative and hypnotic effects of benzodiazepines 
develop tolerance earlier as compared with other therapeutic 
effects of benzodiazepines, and tolerance occurs much faster 
with shorter half-life agents.20,21 However, benzodiazepines 
appear to have continued efficacy against anxiolysis even 
with long-term use, and some studies have attributed this as 
Table 1  Demonstrates the average midazolam and fentanyl doses required in patients with use of opioids and other psychotropic 
agents
Psychotropic medication class Midazolam (mg) p value Fentanyl (mcg) p value
Opioids: 0.04 0.09
Users: 2.7 ± 1.3 123 ± 60
Nonusers: 2.5 ± 1.1 114 ± 48
Benzodiazepines: 0.01 0.05
Users: 2.9 ± 1.4 129 ± 54
Nonusers: 2.5 ± 1.6 116 ± 54
Antidepressants: 0.05 0.17
Users: 2.8 ± 1.2 126 ± 52
Nonusers: 2.5 ± 1.2 117 ± 54
Pregabalin/gabapentin: 0.81 0.62
Users: 2.6 ± 1.5 122 ± 63
Nonusers: 2.6 ± 1.2 118 ± 53
p values obtained by performing t-tests through SAS software are also represented in this table.
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reason for lack of dose escalation in chronic benzodiazepine 
users.20,22 Overall, both opioids and benzodiazepines aug-
ment each other’s effects during sedation, and the increase in 
dose requirements during perioperative period is likely due 
to tolerance exhibited to both agents.10,11,20
To our knowledge, this is the first study that demonstrated 
not only increased midazolam requirements in patients with 
history of prescription benzodiazepine use, but also signifi-
cantly increased midazolam requirements in patients with 
history of prescription antidepressant use (SSRIs and SNRIs) 
in patients undergoing port placement. In addition, these 
patients also required increased doses of fentanyl during port 
placement when compared with non-users, however, these 
results were not significant at the 95% confidence interval. 
The exact mechanism through which antidepressant users 
require higher benzodiazepines is unclear. However, it is likely 
multifactorial, with a combination of biochemical changes 
and variable neurotransmitter availability in the central ner-
vous system (CNS) caused by multiple psychotropic medi-
cations and presence of somatic and psychological factors 
during the perioperative period.23-25 In our study, anxiety and 
mood changes during the procedure likely potentiate pain 
perception, which subsequently results in higher midazolam 
and fentanyl doses in patients with history of prescription 
antidepressant use. Patients with preoperative depression 
and anxiety reported having greater amounts of postopera-
tive pain and resultant increase in opioid use.25,26 One study 
performed psychological assessment (that included patient 
health questionnaire among other questionnaires) in all 
patients prior to oropharyngeal surgery. The study indicated 
that significantly more opioids were needed for higher post-
operative pain which, in turn, was correlated to psychologi-
cal anticipation of higher pain and/or with higher degree of 
clinical depression.25 Although these studies looked at post-
operative pain, similar rationale can be extrapolated to the 
intraoperative period.
To our knowledge, this is the first study that has looked 
at increased sedation requirements during a discrete mini-
mally invasive procedure performed under moderate seda-
tion in patients with known history of prescription opioid 
use. Central venous ports were chosen as an ideal index pro-
cedure to limit procedural heterogeneity such as anatomical 
location, procedural duration, and procedure -related pain. 
Port placement is a relatively standardized procedure that is 
short in duration, involves minimal intraprocedural discom-
fort, and has little to no postprocedural pain.
Approximately, 1.8 million new cases of cancer are 
expected to be diagnosed in 2020 in United States, a signif-
icant portion of whom will require central venous access 
devices (i.e., port) for infusion of chemotherapy.17 Therefore, 
identifying patients who have been on opioids for ≥ 1 week 
can allow interventionalists to provide optimal preproce-
dural sedation planning.
This study does have some limitations. It is a retrospec-
tive study at a single institution, and data was collected on 
a single procedure type (port placement). Additional lim-
itations include variable strengths and durations of use of 
opioids and other psychotropic agents (ranging from 1 week 
to several months). Also, patient-reported pain scores can 
be highly subjective and would be difficult to account for. 
Furthermore, nurses and/or physicians were not blinded to 
patient’s medical history of opioid and/or psychotropic use, 
potentially introducing an element of bias.
Conclusion
Patients with history of opioid use require significantly 
higher sedation drug doses compared with nonusers, and 
similar trends can be seen in patients with history of use of 
benzodiazepines and antidepressants. Anticipating higher 
requirements of these medications in these patients can 
allow planning for other alternatives for analgesia/anes-
thesia, increase patient satisfaction, and allow timely com-
pletion of minimally invasive procedures performed under 
moderate sedation. More patient and provider awareness are 
needed on this topic, as health care policy has been moving 
more and more toward value-based health care, with patient 
satisfaction surveys being one of its indicators.
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